Insilico Medicine’s Generative AI Patent Provides Advantage in AI Drug Discovery Race

by Andrii Buvailo, PhD          Biopharma insight

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   6765    Comments 2
Topics: Emerging Technologies   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Companies are increasingly turning to generative artificial intelligence (AI) to develop new therapeutics, giving biotech companies with patents on these technologies a distinct advantage in the tech-enabled pharmaceutical future. One of the pioneers in using generative AI to process biological and chemical data in order to design new molecules is biotech company Insilico Medicine. The Company filed a patent application on its mutual information adversarial autoencoder in 2018 – and that patent was approved in 2022. 

The patent covers Insilico’s proprietary system for using generative AI to produce novel small molecules that can be further synthesized, tested and advanced into clinical assets – the algorithmic backbone to its Chemistry42 engine that has produced new possible treatments for diseases like fibrosis, cancer, and COVID-19.

The process covered by the patent describes the use of deep neural networks(DNNs) – machine learning modules which process data and predict new outputs in order to “generate novel objects that are indistinguishable from data objects.” 

Importantly, the patent covers a computer method for generating an object that satisfies a condition using one or more deep neural networks. Not only does the patent cover using DNNs to design a new molecule, but also the processing of data to arrive at that point, the comparison between the new molecule and the desired molecule, the selection of an object best meeting the desired conditions, obtaining a physical form of the new structure, and validating that physical form. 

Fig 1. Combining various state-of-the-art machine learning methods, Chemistry42 delivers diverse, high-quality molecular structures within hours. As the structures are generated, they are dynamically assessed using the reward and scoring modules in the platform.

 

Continue reading

This content available exclusively for BPT Mebmers

Topics: Emerging Technologies   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Comments:

  • Joseph Pareti 2023-12-11 18:50

    i have seen a similar approach to design small molecules in this gordon bell award winning research: https://journals.sagepub.com/doi/pdf/10.1177/10943420211010930

    reply
    • BiopharmaTrend 2023-12-14 16:41

      Thank you for this reference, Joseph. Could you please elaborate on the similarities?

      reply

Leave a Reply

Your email address will not be published. Required fields are marked *